A patient-focused look at how migraine changes around periods and other hormonal shifts, whether acute treatment still works, why short-term prevention is often not discussed, how estrogen decisions are handled, and where patients see the biggest gaps in hormonal migraine care.
Audience: Patients living with migraine
Countries: 4
Completion Rate: 79.6%
SGID: 8957951
-Hero findings
– Quick Read — Key Findings
Migraine can change around menstruation, perimenopause, pregnancy, contraception, hormone therapy, and other periods of hormonal fluctuation. For patients, the challenge is often not simply having more attacks. It is that the attacks may feel different, arrive less predictably, or respond differently to the treatment that usually works.
The World Health Organization still ranks migraine among the leading causes of neurological disability and notes it is more common in women, partly because of hormonal influences, while the American Migraine Foundation calls period-related attacks among the hardest to treat and describes acute treatment, short-term mini-prevention, and continuous prevention as options that depend on the person and how predictable the attacks are. The MDForLives survey adds the patient’s voice across menstruation, contraception, the perimenopause and menopause transition, and hormone therapy, and the clearest story is not that every hormonal change worsens migraine the same way, but that many patients see a pattern while their care does not always shift to match it.
42.5% say attacks that coincide with a period or hormonal fluctuation are significantly worse, with longer duration, higher pain intensity, and greater difficulty treating them.
Another 27.5% call the attacks only slightly worse, 12.5% notice no difference, and 7.5% actually find hormone-linked attacks milder. That range is the point: two people with the same migraine diagnosis can face very different levels of disability depending on where an attack lands in the hormonal cycle.
42.5% report a moderate increase in monthly migraine days after a major hormonal shift, while 20.0% describe a severe worsening in frequency and intensity.
Those transitions can mean entering perimenopause or menopause, starting or stopping hormonal birth control, pregnancy, or beginning gender-affirming hormone therapy, and change does not always mean worsening, 10.0% report stability and 5.0% real improvement. Still, the most common experience by far is simply more migraine days each month.
22.5% say acute medicines are much less effective during hormonally triggered attacks, and another 22.5% say they are slightly less effective.
Acute medication much less effective
Acute medication equally effective
Provider never suggested mini-prophylaxis
Currently use mini-prophylaxis with good success
A quarter say acute medication works about the same and 15.0% say it works faster, so there is no single response, but the bigger gap is prevention: 53.8% say a provider has never suggested or discussed mini-prophylaxis, a short preventive plan timed around a predictable hormonal window. The American Migraine Foundation lists several such options for menstrual migraine, from certain triptans and NSAIDs to magnesium and selected hormonal strategies, though none suit everyone and timing gets harder when cycles are irregular.
41.0% are somewhat satisfied with how a primary healthcare provider or neurologist addresses the hormone-migraine connection, but say treatment remains mainly standard and non-hormonal.
Another 33.3% say hormonal factors have never even been evaluated in their appointments, so the gap is less about whether a clinician listens than whether the information actually changes tracking, prevention, medication timing, or referral. Estrogen decisions add another layer: 23.1% say a provider stopped or refused estrogen-containing therapy over stroke concerns tied to migraine with aura. The 2024 CDC guidance does classify combined hormonal contraceptives as not recommended for migraine with aura, but that applies to contraception and should not be assumed to cover menopausal hormone therapy or every other hormonal treatment.
33.3% identify the lack of medication specifically approved for hormonal migraine as the single biggest gap, while 28.2% point to difficulty predicting irregular cycles or sudden hormone drops.
Outside prescriptions, 35.9% have tried targeted supplements like magnesium, vitamin B2, riboflavin, or CoQ10, and another 35.9% have changed lifestyle habits such as sleep, diet, or blood-sugar management, while a quarter have tried no non-prescription approach and wearable neuromodulation is still rare here. The open-ended answers carry a consistent message: patients want the hormonal link recognized sooner, prevention timed more proactively, clearer information about their options, and care that adapts as a new life stage reshapes the pattern, and several describe the quiet emotional weight of unpredictable attacks and the frustration of having to find the hormone-migraine connection on their own.
The survey describes patients who often know their migraine shifts with hormones, some with more severe attacks, others with more migraine days after a major hormonal change, and many finding acute treatment less reliable. Yet short-term prevention is often never discussed, a third say hormonal factors have never been evaluated, and estrogen decisions can add confusion once migraine with aura enters the conversation.
The next step is not to treat every migraine as hormonal or to expect one hormone-based fix to suit everyone; it is to make the pattern clinically visible, asking about timing, life stage, contraception, and hormone therapy, checking how medication performs across attack types, using prevention when the pattern is predictable, and explaining risk decisions in language patients can act on. The gap narrows the moment the hormone-migraine connection actually changes what happens next.
You have read the summary
Common questions about menstrual migraine, perimenopause, mini-prevention, migraine with aura, estrogen, and tracking hormone-linked attacks.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
